In this region, Europe cancer diagnostics is projected to reach USD 13.02 billion by 2024 from USD 5.16 billion in 2016, at a CAGR of 12.3% in the forecast period 2017 to 2024.
The major factors driving the growth of this market are the rise in the aging population in European countries and government initiatives. These factors increase the demand for cancer diagnostic products.
Based on geography, the Europe cancer diagnostics market is segmented into 11 geographical regions, such as,

Germany,
France,
United Kingdom,
Italy,
Spain,
Russia,
Turkey,
Belgium,
Netherlands,
Switzerland and
Rest of Europe.

Europe cancer diagnostics market competition by top players including -
Siemens Healthcare is going to dominate the cancer diagnostics market, by imaging following with Hologic Inc., Becton, Dickinson and Company. Thermo Fisher Scientific, Inc. is going to dominate the cancer diagnostics market, by platform based following with Illumina, Inc. along with others such as Roche Diagnostics, Abbott Laboratories, Inc., QIAGEN.
The Europe cancer diagnostics market is segmented on the basis of technology, application and geography. The Europe cancer diagnostics market is segmented into 2 types- platform based and instrument based.
In 2017, the cancer diagnostics instrument based segment is expected to dominate the market with a share of 67.5% and is expected to continue this trend till 2024.

Cancer diagnostics platform based market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), DNA microarrays, flow cytometry and others. Cancer diagnostics instrument based market is segmented into imaging and biopsy.
Imaging is further segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography- computed tomography (PET-CT), mammography and ultrasound.
On the basis of application, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma and others.